Experience

Janux Therapeutics

• United States
• Biotechnology
• 1 - 100 Employee

• Chief Strategy Officer

  • Feb 2022 - 1 year 11 months

  San Diego, California, United States



EMD Serono, Inc.

• Pharmaceutical Manufacturing
• 700 & Above Employee

• Global Head of Clinical Development Strategy and Innovation

  • Jun 2020 - Mar 2022

  Billerica, Massachusetts, United States Responsible for the generation of the Clinical Oncology Franchise Strategy for all Merck KGaA Oncology assets. Accountable for strategic cross-functional interrogation and analysis of tumor specific competitive landscapes to identify tactical clinical study development that supports the Global Oncology Franchise Strategy. Development leader for 6 cross-functional Tumor Strategy Teams that defines opportunity space within indications. Ensures Strategic alignment of Global Program Teams to… Show more Responsible for the generation of the Clinical Oncology Franchise Strategy for all Merck KGaA Oncology assets. Accountable for strategic cross-functional interrogation and analysis of tumor specific competitive landscapes to identify tactical clinical study development that supports the Global Oncology Franchise Strategy. Development leader for 6 cross-functional Tumor Strategy Teams that defines opportunity space within indications. Ensures Strategic alignment of Global Program Teams to tumor strategies. Establishes and maintains a systematic approach to internal and external innovation evaluations to identify strategic approaches to asset partnerships, BD&L activities and clinical strategies to deliver on Franchise goals. Aligns Executive Leadership team on Oncology Portfolio and Innovation prioritization.

• Sr Vice President, Global Program Leader (PgL), Immuno-Oncology (Avelumab)

  • May 2016 - Mar 2022

  Billerica, MA Senior Biopharma Executive with over 25 years of broad cross-functional drug development experience from preclinical through launched product lifecycle development across multiple therapeutic areas. Deep cross-functional experience and a clear view of performance drivers, prioritization choices that maximize asset and Organizational value and building strong teams by creating a compelling and motivating vision. Extensive experience in Organizational vision, governance and operations, Corporate… Show more Senior Biopharma Executive with over 25 years of broad cross-functional drug development experience from preclinical through launched product lifecycle development across multiple therapeutic areas. Deep cross-functional experience and a clear view of performance drivers, prioritization choices that maximize asset and Organizational value and building strong teams by creating a compelling and motivating vision. Extensive experience in Organizational vision, governance and operations, Corporate business development and licensing, Program Leadership, Project Management, Alliance and Risk management. Specialist in Strategic Management principles including strategic and tactical development, strategic competitive intelligence and cross-functional integration. Member of Oncology Franchise Leadership Team. Recognized for excellence in Drug development at Merck Serono (CEO award). Development Program Led at EMD Serono: Avelumab (PD-L1)



Bayer

• Chemical Manufacturing
• 700 & Above Employee

• Vice President, Senior Global Program Head (GPH), Oncology

  • Apr 2015 - May 2016

  Whippany, NJ Senior Global Program Head with responsibility to develop and oversee disease indication pipeline portfolio and GPH oversight (hematology). Member of the Global Development Specialty Medicine (ONC) Management team to ensure programmatic strategy alignment with business needs and objectives in Oncology, Ophthalmology and Hematology. SMTASC provides franchise plans, strategic guidance to GPT’s, undertakes strategic and budgetary Portfolio evaluations, making recommendations to fund or cancel… Show more Senior Global Program Head with responsibility to develop and oversee disease indication pipeline portfolio and GPH oversight (hematology). Member of the Global Development Specialty Medicine (ONC) Management team to ensure programmatic strategy alignment with business needs and objectives in Oncology, Ophthalmology and Hematology. SMTASC provides franchise plans, strategic guidance to GPT’s, undertakes strategic and budgetary Portfolio evaluations, making recommendations to fund or cancel assets, and undertakes cross-functional issue resolution impeding asset progress that cannot be resolved at the GPT level. Full organizational accountability to deliver value based products to patients. Responsible for global leadership of the drug development programs on behalf of R&D and asset representation internally and externally. Responsible as the single point of contact for the asset and presents the project to all Governance committees, including the highest level of Governance within Bayer, the Global Product Development Committee (GPDC). Member of the Specialty Medicine Therapeutic Area Steering Committee (SMTASC) Committee established to ensure programmatic strategy alignment with business needs and objectives in Oncology, Ophthalmology and Hematology. SMTASC provides franchise plans, strategic guidance to GPT’s, undertakes strategic and budgetary Portfolio evaluations, making recommendations to fund or cancel assets, and undertakes cross-functional issue resolution impeding asset progress that cannot be resolved at the GPT level. Development Programs Led at Bayer include: Mesothelin-ADC (immunotoxin), Vantictumab and Ipafricept (WnT inhibitors); Copanlisib (PI3K); BAY 1082439 PI3K

• Senior Director, Global Program Head (GPH), Oncology

  • Dec 2012 - Apr 2015

  whippany, NJ Global Program Head of Global Project Teams (GPT). Full organizational accountability to deliver value based products to patients. The GPH is responsible for global leadership of the drug development project on behalf of R&D. The GPH represents the project internally and externally, and acts as the CEO of the Global Project Team (GPT). The GPH is the single point of contact for the asset and presents the project to all Governance committees, including the highest level of Governance within… Show more Global Program Head of Global Project Teams (GPT). Full organizational accountability to deliver value based products to patients. The GPH is responsible for global leadership of the drug development project on behalf of R&D. The GPH represents the project internally and externally, and acts as the CEO of the Global Project Team (GPT). The GPH is the single point of contact for the asset and presents the project to all Governance committees, including the highest level of Governance within Bayer, the Global Product Development Committee (GPDC). Member of the Specialty Medicine Therapeutic Area Steering Committee (SMTASC) Committee established to ensure programmatic strategy alignment with business needs and objectives in Oncology, Ophthalmology and Hematology. SMTASC provides franchise plans, strategic guidance to GPT’s, undertakes strategic and budgetary Portfolio evaluations, making recommendations to fund or cancel assets, and undertakes cross-functional issue resolution impeding asset progress that cannot be resolved at the GPT level. Officially Recognized by Bayer Global Development as a High Performing Individual (HPI). Authorized by Bayer Group Management Board 2013. Development Programs Led at Bayer include: Mesothelin-ADC (immunotoxin), Vantictumab and Ipafricept (WnT inhibitors); Copanlisib (PI3K); BAY 1082439 PI3K



Amgen

• United States
• Biotechnology Research
• 700 & Above Employee

• Director, R&D Program Management and Strategic Operations; Global Program Manager

  • Oct 2002 - Dec 2012

  Thousand Oaks, CA Global Program Management Leader on Product Strategy Teams (PST) responsible for designing and implementing comprehensive, cross-functionally integrated global clinical, regulatory, commercial, payer and manufacturing strategies, leading to go/no go development decisions for commercialization of the new molecular entities. Oncology antiangiogenic PMSO leader responsible for analyzing scientific and pharma developments in the antiangiogenic field, generating competitive intelligence… Show more Global Program Management Leader on Product Strategy Teams (PST) responsible for designing and implementing comprehensive, cross-functionally integrated global clinical, regulatory, commercial, payer and manufacturing strategies, leading to go/no go development decisions for commercialization of the new molecular entities. Oncology antiangiogenic PMSO leader responsible for analyzing scientific and pharma developments in the antiangiogenic field, generating competitive intelligence tumor landscape maps, assessing in-licensing and out-licensing opportunities and new target opportunities and developing antiangiogenic portfolio strategies for pipeline products. Therapeutic areas at Amgen: Oncology (8yrs), Ophthalmology (2yrs), Inflammation (8yrs), Metabolic disorders (8yrs) and Nephrology (2yrs). Development Programs Led at Amgen included: Trebananib (AMG 386) (antiangiogenic, oncology and ophthalmology); AMG 706 (antiangiogenic, oncology); AMG 753 (antiangiogenic, oncology, ophthalmology); AMG 780 (antiangiogenic, ophthalmology, oncology); AMG 429 (antiangiogenic; oncology); AMG 479 (IGF-1R, oncology); talimogene laherparepvec (T-Vec, Oncolytic HSV Oncology); AMG 476, AMG 538 (inflammation, p-38 inhibitors); Pegsunercet (inflammation, TNFR1), AMG 245 (Myostatin inhibitor); AMG 745 (Myostatin inhibitor); AMG 076 (MCHR1 inhibitor; obesity); AMG 685 (Sclerostin inhibitor: Bone); AMG 785 (Sclerostin inhibitor: Bone); Aranesp, Epogen, (Nephrology), Alcon collaboration (17 pre-clinical molecules for Ophthalmic development). Show less



Miravant Medical Technologies

• Head of Chemistry Research and Product Development

  • Jan 1992 - Oct 2002

  Santa Barbara, California Area Member of the senior leadership team responsible for defining overall scientific, governance and commercialization objectives for the company. Head of chemistry research responsible for the research and pre-clinical development of, and portfolio management of, New Molecular Entities, formulations, manufacturing scale-up improvements and chemistry support activities to Commercial launch for disease indications in oncology, ophthalmology, cardiovascular and other proliferative diseases… Show more Member of the senior leadership team responsible for defining overall scientific, governance and commercialization objectives for the company. Head of chemistry research responsible for the research and pre-clinical development of, and portfolio management of, New Molecular Entities, formulations, manufacturing scale-up improvements and chemistry support activities to Commercial launch for disease indications in oncology, ophthalmology, cardiovascular and other proliferative diseases. Responsible for all intellectual property acquisition and defense, out-licensing and in-licensing evaluations and partner and contract manufacturing alliance management. Responsible for grant acquisition and management and to represent research at scientific meetings. Development Programs Led at Miravant included: SnET2, MRVT633, MRVT6401 Show less